At a Glance
- Company: Disc Medicine
- Location: Watertown, Massachusetts
- Headline figures: ~50 employees (20% headcount); bitopertin halted
- Focus area: Congenital erythropoietic porphyria (CEP) therapy
- Next steps: Pipeline prioritisation; cost savings
What happened?
Disc Medicine announced workforce reductions affecting approximately 20% of employees (~50 staff) on 4 March 2026 following an FDA complete response letter rejecting bitopertin, its lead candidate for congenital erythropoietic porphyria (CEP). The company simultaneously halted all CEP development activities.
Why does it matter?
CEP rejection eliminates a key value driver in rare haematology; layoffs preserve cash for prioritise core erythropoiesis programmes amid biotech funding constraints. Restructuring extends runway while seeking partners or pivots for remaining assets.
Who’s behind it?
Disc Medicine focuses on erythroid disorders; leadership cited regulatory feedback requiring unfeasible additional studies. Cuts target redundant functions post-programme termination.
How was it achieved?
FDA CRL cited insufficient efficacy data despite phase 2/3 completion; bitopertin (ferroportin inhibitor) failed to meet non-inferiority to supportive care. Restructuring saves ~$25M annually.
What’s next?
Refocus on approved/rejected erythropoiesis assets; explore partnerships. Layoffs complete Q2 2026 with severance; cash supports operations through key catalysts.
What are people saying?
Disc exec: “Prudent measures… advance highest-priority programmes.” Analysts: “Necessary reset post-CEP setback.”